Changes in Beneficial Ownership · 4
Lyell Immunopharma, Inc.
LYELNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-08112026_080842.xml
Filing details
- Report period
- 2026-08-10
- Issuer
- Lyell Immunopharma, Inc.
- Issuer CIK
- 0001806952
- Trading symbol
- LYEL
Reporting owner 1
- Name
- Seely Lynn
- Reporting owner CIK
- 0001327111
- Relationship
- Director · Officer
- Officer title
- President and CEO
- Address
- C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-10 | S · Form 4 | 390[F1] | D | 14.34[F2] | 73,488 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.↩ 1
- F2
- The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.22 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.↩ 1
Signature 1
- Signed
- /s/ Mark Meltz, Attorney-in-Fact
- Date
- 2026-08-11
Company context
Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. Lyell’s lead product candidate, LYL314, is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of the responses as compared to the approved CD19-targeted CAR T-cell therapies for the treatment of large B-cell lymphoma. The PiNACLE trial is an ongoing single-arm pivotal trial evaluating LYL314 in patients with large B-cell lymphoma that has relapsed and/or been refractory to two or more lines of prior therapy. The Lyell LyFE Manufacturing Center™ has commercial launch capability and can manufacture more than 1,200 CAR T-cell doses at full capacity. To learn more, please visit www.lyell.com.